Clinical Trial Update: Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adenosine signaling modulation in combination with immune checkpoint inhibition for hormone-sensitive oligometastatic prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Catherine Spina | Conditions: Oligometastatic Prostate Cancer | Phase 2 | Status: RECRUITING